These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3310859)

  • 1. Anti-LAV/HTLV-III antibodies in high and low risk groups.
    Zanetti AR; Zehender G; Tanzi E; Rumi MG; Mari D; Ferroni P
    Antibiot Chemother (1971); 1987; 38():167-73. PubMed ID: 3310859
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of a new confirmatory assay for antibodies against lymphadenopathy-associated virus (LAV)/human T-lymphotropic virus type III (HTLV III).
    Abb J
    Vox Sang; 1986; 51(3):233-5. PubMed ID: 3544497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of HTLV III/LAV and other viral antibodies in normal and at risk populations.
    Ferrante P; Nardi G; Zanchetta N; Salvioni PM; Pagano A
    Boll Ist Sieroter Milan; 1986; 65(5):357-60. PubMed ID: 3030363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for antibodies to HTLV-III/LAV in our population. A word of caution.
    Zafar MN
    J Pak Med Assoc; 1987 Apr; 37(4):84-5. PubMed ID: 3108550
    [No Abstract]   [Full Text] [Related]  

  • 5. Screening for anti-HTLV-III/LAV antibody in high-risk subjects: sensitivity and specificity of commercial tests.
    Lantin JP; Peitrequin R; Frei PC
    Int Arch Allergy Appl Immunol; 1987; 82(3-4):487-9. PubMed ID: 3553029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seropositivity to LAV/HTLV-III in 11 European countries.
    Ebbesen P; Melbye M; Jeffries J; Antonen J; Valle SL; Suni J; Ranki A; Krohn K; Chermann JC; Koch MA
    Eur J Cancer Clin Oncol; 1986 Dec; 22(12):1453-6. PubMed ID: 3474150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lymphopathic HTLV-III-LAV infection and acquired immunodeficiency syndrome].
    Pokrovskiĭ VV
    Ter Arkh; 1986; 58(10):151-4. PubMed ID: 3541273
    [No Abstract]   [Full Text] [Related]  

  • 8. High prevalence and high titers of LAV/HTLV-III antibodies in healthy hemophiliacs in the midwestern United States.
    Goldsmith JC; Dewhurst S; Hedenskog M; Casareale D; Volsky DJ
    Am J Med; 1986 Oct; 81(4):579-83. PubMed ID: 3532787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-Hodgkin's lymphoma, HTLV-III/LAV, and HTLV-III/LAV antibody in the wife of a man with transfusion-acquired AIDS.
    Duncan ED; Miller HJ; McKeever WP
    Am J Med; 1986 Nov; 81(5):898-900. PubMed ID: 3640579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies to human immunodeficiency virus (HTLV-III/LAV) in people from Lagos and Cross River States of Nigeria.
    Okpara RA; Akinsete I; Williams EE; Schneider J; Wendler I; Hunsmann G
    Acta Haematol; 1988; 79(2):91-3. PubMed ID: 3124480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of LAV/HTLV-III-positive blood donors.
    Laufs R
    Haematol Blood Transfus; 1987; 31():434-5. PubMed ID: 3481760
    [No Abstract]   [Full Text] [Related]  

  • 12. [Epidemiology of infection by LAV/HTLV-III virus in hemophiliacs multitransfused in France. Results of a survey conducted by 28 hemophilia centers].
    Sultan Y
    Nouv Rev Fr Hematol (1978); 1986; 28(5):327-9. PubMed ID: 3643509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sero-epidemiology of HTLV-III/LAV antibodies in French-speaking Switzerland].
    Stroun J
    Rev Med Suisse Romande; 1985 Nov; 105(11):1055-7. PubMed ID: 3003866
    [No Abstract]   [Full Text] [Related]  

  • 14. [Safety of immunoglobulins in view of the transmission of LAV/HTLV-III].
    Sugg U; Kaufmann R; Gürtler L; Schneider W
    Beitr Infusionther Klin Ernahr; 1987; 18():39-41. PubMed ID: 3326597
    [No Abstract]   [Full Text] [Related]  

  • 15. [LAV/HTLV-III infection among homosexual men; prevalence, incidence and possible co-factors].
    de Wolf F; Coutinho RA; Goudsmit J; Krone W; Schellekens P; Danner S
    Ned Tijdschr Geneeskd; 1986 Nov; 130(48):2180-3. PubMed ID: 3643452
    [No Abstract]   [Full Text] [Related]  

  • 16. [Anti-LAV/HTLV III antibodies in wives of seropositive hemophilic patients].
    Bardin JM; Maisonneuve P; Nguyen M; Pinon F; Sultan Y
    Presse Med; 1986 Oct; 15(33):1686-7. PubMed ID: 2947123
    [No Abstract]   [Full Text] [Related]  

  • 17. [Prevalence of antibodies against HTLV-III/LAV in homosexuals and drug addicts from a population in Madrid].
    Alós JI; Rodríguez-Créixems M; Guerrero A; Gómez-Criado C; Romero-Vivas J; Bouza E
    Rev Clin Esp; 1986 Sep; 179(4):172-4. PubMed ID: 3464056
    [No Abstract]   [Full Text] [Related]  

  • 18. Specificity of human immunodeficiency virus (LAV/HTLV-III)-reactive antibodies in African sera from southeastern Tanzania.
    Schüpbach J; Tanner M
    Acta Trop; 1986 Sep; 43(3):195-206. PubMed ID: 2877546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of HTLV-III/LAV in household contacts of patients with confirmed AIDS and controls in Kinshasa, Zaire.
    Mann JM; Quinn TC; Francis H; Nzilambi N; Bosenge N; Bila K; McCormick JB; Ruti K; Asila PK; Curran JW
    JAMA; 1986 Aug; 256(6):721-4. PubMed ID: 3014178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of acquired immunodeficiency syndrome (AIDS) retrovirus antibody by lymphadenopathy-associated virus (LAV) enzyme immunoassay in low- and high-risk populations.
    Ragni MV; Lewis JH; Bracken M; Toth R; Stokes J; Steffensen DO
    Transfusion; 1986; 26(3):299-301. PubMed ID: 3010516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.